Darryl Maher
Fortuna: 1 132 $ al 30/06/2026
Fortuna: 1 132 $ al 30/06/2026
Darryl Maher worked at CSL Behring (Australia) Pty Ltd. as Vice President-Research & Development.
Dr. Maher served as President of the Australian Pharmaceutical Physicians Association.
Dr. Maher was an Independent Non-Executive Director at Cynata Therapeutics Ltd. from 2020 to 2026.
Dr. Maher earned a doctorate from the University of Melbourne.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 06/07/2026 | 116.666 ( 0,05 % ) | 1 132 $ | 30/06/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| CYNATA THERAPEUTICS LIMITED | Director/Miembro de la Junta | 06/07/2026 |
Australian Pharmaceutical Physicians Association | Presidente | - |
CSL Behring (Australia) Pty Ltd.
CSL Behring (Australia) Pty Ltd. BiotechnologyHealth Technology Engages in R&D and production of biotechnology products | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
University of Melbourne
University of Melbourne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cynata Therapeutics Ltd.
Cynata Therapeutics Ltd. BiotechnologyHealth Technology Engages in stem cell research and development services | Health Technology |
CSL Behring (Australia) Pty Ltd.
CSL Behring (Australia) Pty Ltd. BiotechnologyHealth Technology Engages in R&D and production of biotechnology products | Health Technology |
Australian Pharmaceutical Physicians Association |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.